Optimus Medical

Clinical research site in San Francisco, California · 500 PARNASSUS AVE, 11 LONG, BOX 0210, SAN FRANCISCO, CA 94143-2203 · (415) 353-1383

As of September 2026, 47 paid clinical trials are recruiting at Optimus Medical in San Francisco, California. Active studies at this site cover conditions such as B Acute Lymphoblastic Leukemia, Neuroblastoma and Acute Myeloid Leukemia. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 4, 2026.

New trial at Optimus Medical? We'll email you when one opens.

Recruiting clinical trials at Optimus Medical (47)

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

for Coronavirus Disease (COVID-19)

58 locations incl. Paradise Valley

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06667700·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

for Non-Small Cell Lung Cancer, NSCLC

28 locations incl. Gilbert

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06162221·Phase 1, Phase 2·Recruiting·Listed Dec 2023

Apply to this trial

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

for Non-Small-Cell Lung Cancer

20 locations incl. Fullerton

Sponsor: ArriVent BioPharma, Inc.

Sex: All·Age: 18+

Code: NCT07185997·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

for Multiple Myeloma

17 locations incl. San Francisco

Sponsor: K36 Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05651932·Phase 1·Recruiting·Listed Dec 2022

Apply to this trial

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

for Myasthenia Gravis

17 locations incl. San Francisco

Sponsor: argenx

Sex: All·Age: 18+

Code: NCT06298565·Recruiting·Listed Mar 2024

Apply to this trial

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

for Childhood Extracranial Germ Cell Tumor

382 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: All ages

Code: NCT03067181·Phase 3·Recruiting·Listed Mar 2017

Apply to this trial

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for Ovarian Carcinoma

481 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 35 - 50

Code: NCT04251052·Recruiting·Listed Jan 2020

Apply to this trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for Acute Myeloid Leukemia

330 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05564390·Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

for Metastatic Renal Cell Carcinoma

280 locations incl. Kingman

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05327686·Phase 2·Recruiting·Listed Apr 2022

Apply to this trial

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

206 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554406·Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

216 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06317649·Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

172 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554393·Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

129 locations incl. Tucson

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06672146·Phase 2·Recruiting·Listed Nov 2024

Apply to this trial

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

for Metastatic Salivary Gland Carcinoma

142 locations incl. Dublin

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05408845·Phase 2·Recruiting·Listed Jun 2022

Apply to this trial

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

for Metastatic Dedifferentiated Liposarcoma

238 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06422806·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

for B Acute Lymphoblastic Leukemia

187 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 25

Code: NCT03959085·Phase 3·Recruiting·Listed May 2019

Apply to this trial

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

for Down Syndrome

152 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 1 - 30

Code: NCT04546399·Phase 2·Recruiting·Listed Sep 2020

Apply to this trial

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

for B Acute Lymphoblastic Leukemia

138 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 366 Days - 46

Code: NCT06124157·Phase 2·Recruiting·Listed Nov 2023

Apply to this trial

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

for Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

43 locations incl. San Francisco

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04609046·Phase 1·Recruiting·Listed Oct 2020

Apply to this trial

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

for Acute Myeloid Leukemia

169 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT04293562·Phase 3·Recruiting·Listed Mar 2020

Apply to this trial

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

for Acute Leukemia of Ambiguous Lineage

111 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 365 Days

Code: NCT06317662·Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

for Recurrent Langerhans Cell Histiocytosis

101 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 180 Days - 22

Code: NCT05828069·Phase 2·Recruiting·Listed Apr 2023

Apply to this trial

Project: Every Child for Younger Patients With Cancer

for Adrenal Gland Pheochromocytoma

227 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 25

Code: NCT02402244·Recruiting·Listed Mar 2015

Apply to this trial

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

for Stage I Mixed Cell Type Kidney Wilms Tumor

153 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 30

Code: NCT06401330·Phase 3·Recruiting·Listed May 2024

Apply to this trial

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

for Malignant Glioma

107 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 12 Months - 21

Code: NCT05099003·Phase 1, Phase 2·Recruiting·Listed Oct 2021

Apply to this trial

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

for Anaplastic Kidney Wilms Tumor

172 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 30

Code: NCT04322318·Phase 2·Recruiting·Listed Mar 2020

Apply to this trial

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

for Low Grade Astrocytoma

117 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 2 - 21

Code: NCT04166409·Phase 3·Recruiting·Listed Nov 2019

Apply to this trial

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

for Buccal Mucosa Squamous Cell Carcinoma

87 locations incl. Gilbert

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT04333537·Phase 2, Phase 3·Recruiting·Listed Apr 2020

Apply to this trial

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

for Stage II Nasopharyngeal Carcinoma AJCC v8

75 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 21

Code: NCT06064097·Phase 2·Recruiting·Listed Oct 2023

Apply to this trial

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

for Ganglioneuroblastoma, Nodular

154 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 30

Code: NCT06172296·Phase 3·Recruiting·Listed Dec 2023

Apply to this trial

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

for Acute Lymphoblastic Leukemia

156 locations incl. Birmingham

Sponsor: PedAL BCU, LLC

Sex: All·Age: Up to 22

Code: NCT04726241·Phase 1, Phase 2·Recruiting·Listed Jan 2021

Apply to this trial

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

for Metastatic Malignant Neoplasm in the Lung

202 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 50

Code: NCT05235165·Phase 3·Recruiting·Listed Feb 2022

Apply to this trial

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

for Basal Ganglia Germinoma

95 locations incl. Mobile

Sponsor: Children's Oncology Group

Sex: All·Age: 3 - 29

Code: NCT06368817·Phase 2·Recruiting·Listed Apr 2024

Apply to this trial

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

for Pancreatic Neoplasm

335 locations incl. Birmingham

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 50 - 75

Code: NCT04239573·Recruiting·Listed Jan 2020

Apply to this trial

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

for Ganglioneuroblastoma

143 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 30

Code: NCT03126916·Phase 3·Recruiting·Listed Apr 2017

Apply to this trial

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

for Central Nervous System Nongerminomatous Germ Cell Tumor

141 locations incl. Anchorage

Sponsor: Children's Oncology Group

Sex: All·Age: 3 - 29

Code: NCT04684368·Phase 2·Recruiting·Listed Dec 2020

Apply to this trial

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

for B Acute Lymphoblastic Leukemia Associated With Down Syndrome

72 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 6 - 39

Code: NCT05702645·Recruiting·Listed Jan 2023

Apply to this trial

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

for Childhood Medulloblastoma

102 locations incl. Mobile

Sponsor: Children's Oncology Group

Sex: All·Age: 4 - 21

Code: NCT05382338·Phase 3·Recruiting·Listed May 2022

Apply to this trial

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

for Pleuropulmonary Blastoma

80 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT06647953·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

for Embryonal Rhabdomyosarcoma

164 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT05304585·Phase 3·Recruiting·Listed Mar 2022

Apply to this trial

Showing the 40 most relevant of 47 recruiting trials at this site. Browse all with filters →

Get new-trial alerts for Optimus Medical

We'll email you whenever a new clinical trial starts recruiting at this research site in San Francisco, CA. Unsubscribe anytime.

More research sites in San Francisco

University of California, San Francisco (320 trials)
University of California San Francisco (166 trials)
Power Life Sciences (51 trials)
UCSF (32 trials)
Kaiser Permanente-San Francisco (32 trials)
UCSF Medical Center-Mission Bay (32 trials)
Zuckerberg San Francisco General Hospital (26 trials)
UCSF Medical Center (23 trials)
California Pacific Medical Center-Pacific Campus (22 trials)
UCSF Helen Diller Family Comprehensive Cancer Center (21 trials)

Is this your research site?

This page is built from public ClinicalTrials.gov records. If you work here, we can correct it, send you the patients who apply, and build you a free website from your real studies — verify it with your work email, or read what we do for research sites.

Explore more

Paid clinical trials in San Francisco, CA · California clinical trials